BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 11502806)

  • 1. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
    Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
    Niccoli-Sire P; Murat A; Rohmer V; Gibelin H; Chabrier G; Conte-Devolx B; Visset J; Ronceray J; Jaeck D; Henry JF; Proye C; Carnaille B; Kraimps JL;
    Surgery; 2003 Dec; 134(6):1029-36; discussion 1036-7. PubMed ID: 14668737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for reporting C cell pathology of the thyroid.
    Kaserer K; Scheuba C; Neuhold N; Weinhäusel A; Vierhapper H; Niederle B
    Wien Klin Wochenschr; 2002 Apr; 114(7):274-8. PubMed ID: 12089863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
    Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
    Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
    Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
    Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia.
    Colombo-Benkmann M; Brämswig J; Höppner W; Gellner R; Hengst K; Böcker W; Senninger N
    World J Surg; 2002 Oct; 26(10):1286-90. PubMed ID: 12205548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
    Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.
    Marsh DJ; McDowall D; Hyland VJ; Andrew SD; Schnitzler M; Gaskin EL; Nevell DF; Diamond T; Delbridge L; Clifton-Bligh P; Robinson BG
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):213-20. PubMed ID: 8849577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
    Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
    Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.
    Learoyd DL; Marsh DJ; Richardson AL; Twigg SM; Delbridge L; Robinson BG
    Arch Surg; 1997 Sep; 132(9):1022-5. PubMed ID: 9301617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
    Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Somatic ret proto-oncogene mutations in sporadic C-cell carcinoma of the thyroid gland].
    Frilling A; Bockhorn M; Kalinin V; Liedke M; Kaun M; Broelsch CE
    Chirurg; 1997 Aug; 68(8):789-93. PubMed ID: 9377989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
    Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.